RAPID-PsA Study Showed That Cimzia® (Certolizumab Pegol) Improved Active Psoriatic Arthritis, In Patients Both With And Without Prior TNF Exposure

ACR20 response rates with certolizumab pegol were higher than placebo at weeks 12 and 24 with response observed as early as week 1 in some patients1 Last week the British Society of Rheumatology annual meeting UCB presented results from the RAPID™-PsA study. Data presented from this phase 3 study showed that compared to placebo, certolizumab pegol provided improvements in the signs and symptoms of psoriatic arthritis (PsA) in adult patients, both with and without prior anti-TNF (tumor necrosis factor) exposure1... via Health News from Medical News Today Read More Here..